伊布替尼的不良反应及处理的研究进展

魏赟晨; 李建勇

doi:10.13201/j.issn.1004-2806.2019.05.016

伊布替尼的不良反应及处理的研究进展

魏赟晨,
李建勇^,

- 南京医科大学第一附属医院(江苏省人民医院)血液科(南京, 210029)

详细信息

通讯作者: 李建勇,E-mail:lijianyonglm@126.com

中图分类号: R755

收稿日期: 2018-12-28

Adverse events of ibrutinib and corresponding management

WEI Yunchen,
LI Jianyong^,

More Information

Corresponding author: LI Jianyong, E-mail: lijianyonglm@126.com

Received Date: 28 December 2018

摘要

- 伊布替尼 /
- 不良反应 /
- 处理
Abstract: The B cell receptor (BCR) signaling pathway plays an important role in the development,proliferation and survival of B cell tumors.Inhibition of Bruton tyrosine kinase (BTK),an essential component of the BCR signaling pathway,can block the conduction of BCR signaling pathway,thereby causing apoptosis of malignant B cells and inhibiting their proliferation,migration and adhesion.Ibrutinib is an irreversible BTK inhibitor and is widely used in hematologic malignancies.Although it is well tolerated,there are still some adverse events to be vigilant.Common adverse events including diarrhea,hemorrhage,atrial fibrillation,infection and hematological toxicity are mainly grade 1-2,most of which can be treated symptomatically.However,in severe cases reduction and discontinuation are needed.With the widespread use of ibrutinib,a deeper understanding of its adverse events will help clinicians better apply this drug.This article reviews the adverse events and corresponding management of ibrutinib.
- ibrutinib /
- adverse events /
- management

HTML全文

参考文献(45)

[1]	IMBRUVICA US Prescribing information, August 2018.https://www.imbruvica.com/docs/librariesprovider7/default-document-library/prescribing-information.pdf.
[2]	谢彦, 朱军.套细胞淋巴瘤诊断与治疗中国专家共识(2016版)解读[J].临床血液学杂志, 2017, 30(9):683-686.
[3]	顾建友, 沈建平.初诊弥漫大B细胞淋巴瘤的治疗进展[J].临床血液学杂志, 2018, 31(11):873-878.
[4]	Atkinson BT, Ellmeier W, Watson SP.Tec regulates platelet activation by GPVI in the absence of Btk[J].Blood, 2003, 102:3592-3599.
[5]	Mcmullen JR, Boey EJ, Ooi JY, et al.Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling[J].Blood, 2014, 124:3829-3830.
[6]	O'brien S, Furman RR, Coutre S, et al.Single-Agent Ibrutinib in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia:A 5-Year Experience[J].Blood, 2018, 131:1910-1919.
[7]	Wang ML, Blum KA, Martin P, et al.Long-term follow-up of MCL patients treated with single-agent ibrutinib:updated safety and efficacy results[J].Blood, 2015, 126:739-745.
[8]	O'brien S, Furman RR, Coutre SE, et al.Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma:an open-label, multicentre, phase 1b/2 trial[J].Lancet Oncol, 2014, 15:48-58.
[9]	Byrd JC, Furman RR, Coutre SE, et al.Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia[J].N Engl J Med, 2013, 369:32-42.
[10]	Byrd JC, Brown JR, O'brien S, et al.Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia[J].N Engl J Med, 2014, 371:213-223.
[11]	Burger JA, Tedeschi A, Barr PM, et al.Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia[J].N Engl J Med, 2015, 373:2425-2437.
[12]	Noy A, De Vos S, Thieblemont C, et al.Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma[J].Blood, 2017, 129:2224-2232.
[13]	Dimopoulos MA, Trotman J, Tedeschi A, et al.Ibrutinib for patients with rituximab-refractory Waldenstr?m's macroglobulinaemia (iNNOVATE):an open-label substudy of an international, multicentre, phase 3 trial[J].Lancet Oncol, 2017, 18:241-250.
[14]	Byrd J C, Furman RR, Coutre SE, et al.Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib[J].Blood, 2015, 125:2497-2506.
[15]	Treon SP, Tripsas CK, Meid K, et al.Ibrutinib in Previously Treated Waldenström's Macroglobulinemia[J].N Engl J Med, 2015, 372:1430-1440.
[16]	Quek LS, Bolen J, Watson SP.A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen[J].Curr Biol, 1998, 8:1137-1140.
[17]	Levade M, David E, Garcia C, et al.Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions[J].Blood, 2014, 124:3991-3995.
[18]	Lipsky AH, Farooqui MZ, Tian X, et al.Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib[J].Haematologica, 2015, 100:1571-1578.
[19]	Kamel S, Horton L, Ysebaert L, et al.Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation[J].Leukemia, 2015, 29:783-787.
[20]	Manne BK, Badolia R, Dangelmaier C, et al.Distinct pathways regulate Syk protein activation downstream of immune tyrosine activation motif (ITAM) and hemITAM receptors in platelets[J].J Biol Chem, 2015, 290:11557-11568.
[21]	Yuan Y, Kulkarni S, Ulsemer P, et al.The von Willebrand factor-glycoprotein Ib/V/IX interaction induces actin polymerization and cytoskeletal reorganization in rolling platelets anXd glycoprotein Ib/V/IX-transfected cells[J].J Biol Chem, 1999, 274:36241-36251.
[22]	Chanan-Khan A, Cramer P, Demirkan F, et al.Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS):a randomised, double-blind, phase 3 study[J].Lancet Oncol, 2016, 17:200-211.
[23]	Brown JR.How I treat CLL patients with ibrutinib[J].Blood, 2018, 131:379-386.
[24]	Dreyling M, Jurczak W, Jerkeman M, et al.Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma:an international, randomised, open-label, phase 3 study[J].Lancet, 2016, 387:770-778.
[25]	Farooqui MZH, Valdez J, Martyr S, et al.Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations:a phase 2, single-arm trial[J].Lancet Oncol, 2015, 16:169-176.
[26]	Leong DP, Caron F, Hillis C, et al.The risk of atrial fibrillation with ibrutinib use:a systematic review and meta-analysis[J].Blood, 2016, 128:138-140.
[27]	Brown JR, Moslehi J, O'brien S, et al.Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials[J].Haematologica, 2017, 102:1796-1805.
[28]	Mato AR, Clasen S, Pickens P, et al.Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia[J].Cancer Biol Ther, 2018, 19:1-2.
[29]	Shanafelt TD, Parikh SA, Noseworthy PA, et al.Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)[J].Leuk Lymphoma, 2017, 58:1630-1639.
[30]	Jain P, Keating M, Wierda W, et al.Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib[J].Blood, 2015, 125:2062-2067.
[31]	Thompson PA, Levy V, Tam CS, et al.Atrial fibrillation in CLL patients treated with ibrutinib.An international retrospective study[J].Br J Haematol, 2016, 175:462-466.
[32]	O'brien S, Jones JA, Coutre SE, et al.Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17):a phase 2, open-label, multicentre study[J].Lancet Oncol, 2016, 17:1409-1418.
[33]	Ghez D, Calleja A, Protin C, et al.Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib[J].Blood, 2018, 131:1955-1959.
[34]	Lionakis MS, Dunleavy K, Roschewski M, et al.Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma[J].Cancer Cell, 2017, 31:833-843.e5.
[35]	Chamilos G, Lionakis MS, Kontoyiannis DP.Call for Action:Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways[J].Clin Infect Dis, 2018, 66:140-148.
[36]	Tillman BF, Pauff JM, Satyanarayana G, et al.Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies[J].Eur J Haematol, 2018, 100:325-334.
[37]	Lee R, Nayernama A, Jones SC, et al.Ibrutinib-associated Pneumocystis jirovecii pneumonia[J].Am J Hematol, 2017, 92:E646-E648.
[38]	Dubovsky JA, Beckwith KA, Natarajan G, et al.Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes[J].Blood, 2013, 122:2539-2549.
[39]	De Jesus Ngoma P, Kabamba B, Dahlqvist G, et al.Occult HBV reactivation induced by ibrutinib treatment:a case report[J].Acta Gastroenterol Belg, 2015, 78:424-426.
[40]	Herishanu Y, Katchman H, Polliack A.Severe hepatitis B virus reactivation related to ibrutinib monotherapy[J].Ann Hematol, 2017, 96:689-690.
[41]	Hammond SP, Chen K, Pandit A, et al.Risk of hepatitis B virus reactivation in patients treated with ibrutinib[J].Blood, 2018, 131:1987-1989.
[42]	Tedeschi A, Frustaci AM, Mazzucchelli M, et al.Is HBV prophylaxis required during CLL treatment with ibrutinib?[J].Leuk Lymphoma, 2017, 58:2966-2968.
[43]	Molica S, Levato L, Mirabelli R, et al.Feasibility and safety of therapy with ibrutinib after antiviral control of hepatitis B virus (HBV) reactivation in chronic lymphocytic leukemia patients[J].Leuk Lymphoma, 2018:1-3.
[44]	Burger JA, Keating MJ, Wierda WG, et al.Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia:a single-arm, phase 2 study[J].Lancet Oncol, 2014, 15:1090-1099.
[45]	Wilson WH, Young RM, Schmitz R, et al.Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma[J].Nat Med, 2015, 21:922-926.